Top

Drugs

Published in:

01-08-2003 | Adis Drug Profile

Tenofovir Disoproxil Fumarate

Authors: Therese M. Chapman, Jane K. McGavin, Stuart Noble

Published in: Drugs | Issue 15/2003

Abstract

▴ Tenofovir disoproxil fumarate (tenofovir DF) is a prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor.
▴ In two large, well designed, placebo-controlled clinical trials, tenofovir DF 300 mg/day resulted in significant reductions in HIV-1 RNA from baseline compared with placebo at 24 weeks in antiretroviral-experienced patients with HIV infection. Patients in both treatment groups continued to receive existing stable antiretroviral therapy.
▴ In an extension phase of one trial, these reductions in viral load were maintained after 96 weeks of treatment with tenofovir DF.
▴ Preliminary data from a large, 3-year comparative trial suggest the clinical efficacy of tenofovir DF in combination with baseline antiretroviral therapy is similar to that of stavudine in antiretroviral-naive patients with HIV infection.
▴ Virological substudies showed that viral suppression was maintained in patients who developed new reverse transcriptase mutations during tenofovir DF therapy (in combination with existing stable antiretroviral drugs) for up to 48 weeks. Isolates of HIV infrequently developed the K65R mutation during 96 weeks of tenofovir DF therapy.
▴ Tenofovir DF is generally well tolerated. The most commonly observed adverse events seen with tenofovir DF (in combination with other antiretroviral drugs) were predominantly of a gastrointestinal nature.

Use of tradename is for product identification purposes only and does not imply endorsement.

Cundy KC, Sueoka C, Lynch GR, et al. Pharmacokinetics and bioavailability of the anti-human immunodeficiency viras nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998 Mar; 42(3): 687–90PubMed

Shaw J-P, Sueoka CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14(12): 1824–9PubMedCrossRef

Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998 Mar; 42(3): 612–7PubMed

Gilead Sciences Inc. Viread® (tenofovir disoproxil fumarate) tablets: US package insert [online]. Available from URL: http://www.gilead.com/pdf/viread_pi.pdf [Accessed 2003 Jun 5]

Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J Biol Chem 1998 Oct 16; 273(42): 27250–8PubMedCrossRef

Arimilli MN, Kim CU, Dougherty J, et al. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 1997; 8(6): 557–64

Cherrington J, Mulato AS. Adefovir (PMEA) and PMPA show synergistic or additive inhibition of HIV replication in vitro in combination with other anti-HIV agents [abstract no. 41195 plus poster]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva

Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997 Nov; 36(2): 91–7PubMedCrossRef

Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002 Jul; 55(1): 41–52PubMedCrossRef

10.

Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641–8PubMedCrossRef

11.

Zídek Z, Holý A, Franková D. Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production. Eur J Pharmacol 1997 Jul 23; 331(2–3): 245–52PubMedCrossRef

12.

Zídek Z, Holý A, Franková D. Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects. Int J Immunopharmacol 1997 Sep–Oct 31; 19(9–10): 587–97PubMedCrossRef

13.

Zídek Z, Franková D, Holý A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1α) and cytokine (tumour necrosis factor α, interleukin-10 [IL-10], IL-1β) production. Antimicrob Agents Chemother 2001 Dec; 45(12): 3381–6PubMedCrossRef

14.

Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998 Jul; 42(7): 1568–73PubMed

15.

Van Gelder J, Deferme S, Annaert P, et al. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 2000 Dec; 28(12): 1394–6PubMed

16.

Kearney BP, Flaherty JF, Sayre JR, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine [poster no. 337]. 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

17.

Flaherty JF, Kearney BP, Wolf JJ, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir [abstract no. 336 plus poster]. 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

18.

Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998 Sep; 42(9): 2380–4PubMed

19.

Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001 Oct; 45(10): 2733–9PubMedCrossRef

20.

Kearney BP, Gill SC, Flaherty JF, et al. Effect of demographic variables on the pharmacokinetics of tenofovir DF in HIV-infected patients and healthy subjects [abstract no. A-504]. 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago, 18

21.

Gilead Sciences International. Viread®: European summary of product characteristics. Cambridge: Gilead Sciences International Ltd, 2002

22.

Kearney BP, Liaw S, Yale K, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment [poster]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow

23.

Kearney BP, Flaherty J, Wolf J, et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluations [abstract no. P172 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens, 123

24.

Kearney BP, Damle B, Plummer A, et al. Tenofovir DF (TDF) and didanosine EC (ddl EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions [abstract no. 9026 plus poster]. 14th International AIDS Conference; 2002 July 7–12; Barcelona, 42-3

25.

Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract no. 533 plus poster]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

26.

Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002 Jun 14; 16(9): 1257–63PubMedCrossRef

27.

Squires K, Pierone G, Berger D, et al. Tenofovir DF: a 48-week final analysis from a phase III randomized, double blind placebo controlled study in antiretroviral experienced patients [abstract no. 413-W plus poster]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle

28.

Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results [abstract no. 564b plus poster]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston

29.

Cohen C, Skowron G, Nadler J, et al. Tenofovir DF: a final analysis of the open label extension phase from a 48 week, randomized, double blind, placebo controlled study in antiretroviral experienced patients [poster no. 226]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens

30.

Margot NA, Zhong L, Wulfsohn M, et al. Probability and durability of achieving <50 copies/mL of HIV RNA by treatment intensification with tenofovir DF (TDF) [abstract no. H-1077]. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego, 267

31.

Coakley D, Lamy P, Cheng A, et al. Tenofovir DF (TDF) 300 mg consistently demonstrates anti-HIV activity regardless of baseline demographic characteristics in antiretoviral (ART)-experienced HIV-1-infected patients [abstract no. P56 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens, 65

32.

Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4(2): 87–94PubMed

33.

Naeger LK, Margot NA, Miller MD. Tenofovir (PMPA) is less efficiently removed through pyrophosphorolysis and dinucleotide polyphosphate synthesis than zidovudine (AZT) by HIV-1 wild-type RT and RT mutants [abstract no. 1265 plus poster]. 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 308

34.

Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002 Jul; 46(7): 2179–84PubMedCrossRef

35.

Margot NA, Cheng AK, Lu B, et al. Expanded response analyses of tenofovir DF therapy by baseline resistance genotype and phenotype [abstract no. 1390 plus poster]. 14th International AIDS Conference; 2002 July 7–12; Barcelona, 378

36.

Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002 Jun 14; 16(9): 1227–35PubMedCrossRef

37.

Margot NA, Isaacson E, McGowan I, et al. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J AIDS 2003; 33: 15–21

38.

Margot NA, Johnson A, Coakley DF, et al. Final 48-week genotypic and phentypic analyses of study 907: tenofovir DF added to stable background regimens [poster no. 414-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle

39.

Miller MD, Margot NA, McColl DJ, et al. Genotypic and phenotypic characterization of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efaviranz [poster]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow

40.

Cheng A, Barriere S, Coakley DF, et al. Safety profile of tenofovir DF (TDF) in antiretroviral treatment-experienced patients from randomized, double-blind, placebo-controlled clinical trials [abstract no. 4460 plus poster]. 14th International AIDS Conference; 2002 July 7–12; Barcelona, 382

41.

Flaherty J, Kearney B, Wolf J, et al. Coadministration of tenofovir DF (TDF) and didanosine (ddI): a pharmacokinetic (PK) and safety evaluation [abstract no. I-1729]. 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago, 329

42.

Verhelst D, Monge M, Meynard J-L, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 Dec; 40(6): 1331–3PubMedCrossRef

43.

Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 Dec; 324(6): 342–4PubMedCrossRef

44.

Gilead Sciences Inc. European Commission expands the indication of Viread®, Gilead’s once-daily treatment for HIV, to include treatment-näive patients [online]. Available from URL: http://www.gilead.com/wt/sec/pr_1053732734 [Accessed 2003 Jun 5]

Title: Tenofovir Disoproxil Fumarate
Authors: Therese M. Chapman
Jane K. McGavin
Stuart Noble
Publication date: 01-08-2003
Publisher: Springer International Publishing
Published in: Drugs / Issue 15/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363150-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tenofovir Disoproxil Fumarate

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 15/2003

Tipranavir

Calcineurin Inhibitors in Renal Transplantation

Current Concepts of the Pathogenesis of Acne

Tipranavir

Tipranavir

Early Intervention in Multiple Sclerosis